| scholarly article | Q13442814 |
| P50 | author | Dennis C. Liotta | Q5258252 |
| Sommer S Zimmerman | Q125307341 | ||
| Timothy M Acker | Q125308053 | ||
| P2093 | author name string | Stephen F Traynelis | |
| Brooke M Katzman | |||
| Katie L Strong | |||
| Rose M Santangelo | |||
| P2860 | cites work | Genetic enhancement of learning and memory in mice | Q22010371 |
| Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis | Q22251177 | ||
| Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism | Q24530210 | ||
| Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults | Q24558984 | ||
| Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine | Q24684778 | ||
| X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor | Q27658372 | ||
| Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors | Q27670455 | ||
| Structure of a glutamate-receptor ligand-binding core in complex with kainate | Q27765825 | ||
| Salicylate induces tinnitus through activation of cochlear NMDA receptors | Q28195872 | ||
| The chemical biology of clinically tolerated NMDA receptor antagonists | Q28248958 | ||
| Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases | Q28276144 | ||
| Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans | Q28286171 | ||
| Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists | Q28287381 | ||
| Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95 | Q28290055 | ||
| Glutamate receptor ion channels: structure, regulation, and function | Q28290774 | ||
| Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect | Q28293218 | ||
| Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice | Q28507147 | ||
| Spinophilin regulates the formation and function of dendritic spines | Q28513720 | ||
| Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors | Q28776368 | ||
| Magnesium gates glutamate-activated channels in mouse central neurones | Q29616237 | ||
| Antidepressant effects of ketamine in depressed patients | Q29617327 | ||
| Targeting glutamate synapses in schizophrenia | Q30460392 | ||
| Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data | Q30580986 | ||
| Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. | Q49105286 | ||
| Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists | Q49143194 | ||
| Characterization of the binding site for a novel class of noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists | Q50508039 | ||
| Effects of the cognition impairer MK-801 on learning and memory in mice and rats | Q51020354 | ||
| Common and uncommon behavioural effects of antagonists for different modulatory sites in the NMDA receptor/channel complex. | Q52061505 | ||
| Study of a new schizophrenomimetic drug; sernyl. | Q52771570 | ||
| Syntheses of fluorinated phencyclidine analogs | Q56565617 | ||
| Deuterium isotope effects in studies of drug metabolism | Q57406406 | ||
| Glycine potentiates the NMDA response in cultured mouse brain neurons | Q59050531 | ||
| Amantadine in the Treatment of Parkinson's Disease | Q67214050 | ||
| Isotope effects: definitions and consequences for pharmacologic studies | Q69571647 | ||
| Changes in intracellular pH associated with glutamate excitotoxicity | Q72656556 | ||
| Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine | Q43698580 | ||
| Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia | Q44045578 | ||
| N-methyl-D-aspartate antagonist D-APV selectively disrupts taste-potentiated odor aversion learning | Q44201970 | ||
| Comparative studies of anthraquinone- and anthracene-tetraamines as blockers of N-methyl-D-aspartate receptors | Q44310262 | ||
| Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating. | Q44449900 | ||
| Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects | Q44596549 | ||
| Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users | Q45000247 | ||
| Selective cognitive impairments associated with NMDA receptor blockade in humans | Q45222011 | ||
| A study of the dose dependency of a glycine receptor antagonist in focal ischemia | Q45244171 | ||
| Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket | Q45295826 | ||
| Zinc potentiates agonist-lnduced currents at certain splice variants of the NMDA receptor | Q45975434 | ||
| Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol | Q46142192 | ||
| Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks | Q46199208 | ||
| Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic | Q46547623 | ||
| Subtype-dependence of N-methyl-D-aspartate receptor modulation by pregnenolone sulfate | Q46781045 | ||
| Nickel differentially affects NMDA receptor channels in developing cultured rat neurons | Q46957767 | ||
| Drugs acting at the strychnine-insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex | Q48171940 | ||
| Aminoglycoside neurotoxicity involves NMDA receptor activation | Q48312701 | ||
| A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. | Q48329693 | ||
| Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons | Q48399177 | ||
| Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain | Q48629603 | ||
| Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex | Q48643808 | ||
| Synthesis and beta-adrenergic activities of R-fluoronaphthyloxypropanolamine | Q48738334 | ||
| Four residues of the extracellular N-terminal domain of the NR2A subunit control high-affinity Zn2+ binding to NMDA receptors | Q48892598 | ||
| Identification and mechanism of action of two histidine residues underlying high-affinity Zn2+ inhibition of the NMDA receptor | Q48913312 | ||
| Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial | Q48913482 | ||
| Benzyl-polyamines: novel, potent N-methyl-D-aspartate receptor antagonists | Q48950584 | ||
| Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. | Q42670368 | ||
| A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. | Q42755069 | ||
| Immunohistochemical localization of N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat. | Q30650460 | ||
| A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke | Q31924104 | ||
| The discriminative stimulus effects of N-methyl-D-aspartate glycine-site ligands in NMDA antagonist-trained rats | Q33720690 | ||
| NMDA receptor hypofunction model of schizophrenia | Q33813143 | ||
| Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors | Q33821292 | ||
| Tinnitus Retraining Therapy (TRT) as a method for treatment of tinnitus and hyperacusis patients. | Q33845030 | ||
| Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist | Q33888681 | ||
| Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists | Q34059951 | ||
| International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function | Q34130831 | ||
| Neuroprotective potential of ionotropic glutamate receptor antagonists. | Q34209297 | ||
| Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? | Q34212543 | ||
| Excitotoxic cell death | Q34245367 | ||
| Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones | Q34255679 | ||
| The NMDA receptor as a target for cognitive enhancement | Q34288139 | ||
| The rise and fall of NMDA antagonists for ischemic stroke. | Q34307201 | ||
| Control of assembly and function of glutamate receptors by the amino-terminal domain. | Q34310112 | ||
| The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia | Q34327773 | ||
| A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity | Q34332564 | ||
| A novel family of negative and positive allosteric modulators of NMDA receptors. | Q34360000 | ||
| Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear | Q34364137 | ||
| Synaptic plasticity and learning: selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor antagonist AP5. | Q34454517 | ||
| Subunit arrangement and function in NMDA receptors | Q34466595 | ||
| Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor | Q34503039 | ||
| Glutamatergic mechanisms in schizophrenia | Q34504043 | ||
| Differential effects of enrichment on learning and memory function in NR2B transgenic mice | Q34518861 | ||
| NMDA receptor subunits: function and pharmacology. | Q34579640 | ||
| Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. | Q34756031 | ||
| An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. | Q34881233 | ||
| Associative learning performance is impaired in zebrafish (Danio rerio) by the NMDA-R antagonist MK-801. | Q35141531 | ||
| Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators | Q35415834 | ||
| Specific sites within the ligand-binding domain and ion channel linkers modulate NMDA receptor gating | Q35514668 | ||
| New advances in NMDA receptor pharmacology | Q35570829 | ||
| Clinical trials in traumatic brain injury: lessons for the future | Q35608050 | ||
| Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid. | Q35718367 | ||
| Rationale for and use of NMDA receptor antagonists in Parkinson's disease. | Q35784328 | ||
| Spermine potentiation of recombinant N-methyl-D-aspartate receptors is affected by subunit composition | Q35883550 | ||
| Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. | Q35909916 | ||
| Subunit-selective allosteric inhibition of glycine binding to NMDA receptors | Q35971484 | ||
| TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner | Q36060938 | ||
| Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors | Q36089680 | ||
| Differential binding properties of [3H]dextrorphan and [3H]MK-801 in heterologously expressed NMDA receptors | Q36303035 | ||
| Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox | Q36556801 | ||
| NMDA receptors in clinical neurology: excitatory times ahead | Q36660216 | ||
| A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease | Q36725234 | ||
| Ketamine as a novel antidepressant: from synapse to behavior | Q36905864 | ||
| Learning and memory in conditioned fear extinction: effects of D-cycloserine. | Q36913843 | ||
| Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site | Q36954416 | ||
| Structural rearrangements of NR1/NR2A NMDA receptors during allosteric inhibition. | Q37184815 | ||
| Control of NMDA receptor function by the NR2 subunit amino-terminal domain | Q37418445 | ||
| Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential | Q37548763 | ||
| Glutamate-based antidepressants: 20 years on. | Q37616806 | ||
| Multiple signaling pathways involved in stimulation of osteoblast differentiation by N-methyl-D-aspartate receptors activation in vitro | Q37729509 | ||
| NovelN-methyl-d-aspartate receptor antagonists: a review of compounds patented since 2006 | Q37807432 | ||
| Molecular basis of NMDA receptor functional diversity. | Q37852112 | ||
| Do NMDA antagonists protect against cerebral ischemia: are clinical trials warranted? | Q37859421 | ||
| Noncompetitive excitatory amino acid receptor antagonists | Q37874604 | ||
| Glutamate binding-site ligands of NMDA receptors | Q37968686 | ||
| Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators | Q37978091 | ||
| Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines | Q38254691 | ||
| N1-dansyl-spermine and N1-(n-octanesulfonyl)-spermine, novel glutamate receptor antagonists: block and permeation of N-methyl-D-aspartate receptors | Q39456199 | ||
| Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines | Q39474796 | ||
| Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors | Q39660859 | ||
| Design, Synthesis, and Biological Evaluation of 3-Benzazepin-1-ols as NR2B-Selective NMDA Receptor Antagonists. | Q39722433 | ||
| Mechanism of differential control of NMDA receptor activity by NR2 subunits | Q39858588 | ||
| Synaptic plasticity in the hippocampus: LTP and LTD. | Q40694257 | ||
| The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro | Q41089018 | ||
| Control by asparagine residues of calcium permeability and magnesium blockade in the NMDA receptor | Q41603790 | ||
| Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors | Q41845872 | ||
| Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning | Q42023254 | ||
| The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents | Q42556542 | ||
| Determinants of trapping block of N-methyl-d-aspartate receptor channels. | Q42608277 | ||
| Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus | Q42643759 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1337-52 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | Expert Opinion on Therapeutic Patents | Q5421213 |
| P1476 | title | Novel NMDA receptor modulators: an update | |
| P478 | volume | 22 |
| Q48013669 | A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons. |
| Q38174986 | A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease |
| Q93070846 | Agmatine preferentially antagonizes GluN2B-containing N-methyl-d-aspartate receptors in spinal cord |
| Q55080461 | An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups. |
| Q38101620 | Biological activities of guanidine compounds, 2008 - 2012 update |
| Q39307652 | Current Evidence of Chinese Herbal Constituents with Effects on NMDA Receptor Blockade |
| Q38727831 | Current and Future Issues in the Development of Spinal Agents for the Management of Pain |
| Q47681604 | Cyclopropane derivatives as potential human serine racemase inhibitors: unveiling novel insights into a difficult target |
| Q45937170 | Development of a Computational Approach/Model to Explore NMDA Receptors Functions. |
| Q48826263 | Dorsal striatum metabotropic glutamate receptor 8 affects nocifensive responses and rostral ventromedial medulla cell activity in neuropathic pain conditions. |
| Q36100467 | Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists. |
| Q38292223 | Expert opinion on emerging drugs: chronic low back pain |
| Q34048502 | Glutamate as a neurotransmitter in the healthy brain |
| Q47882701 | Identification of potential Gly/NMDA receptor antagonists by cheminformatics approach: a combination of pharmacophore modelling, virtual screening and molecular docking studies |
| Q38936972 | Ionotropic glutamate receptors: Which ones, when, and where in the mammalian neocortex. |
| Q64064014 | Metabotropic Glutamate Receptor 5 and 8 Modulate the Ameliorative Effect of Ultramicronized Palmitoylethanolamide on Cognitive Decline Associated with Neuropathic Pain |
| Q90686384 | Metallaphotoredox Difluoromethylation of Aryl Bromides |
| Q36373051 | Molecular design of proneurogenic and neuroprotective compounds-allosteric NMDA receptor modulators |
| Q37559812 | Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease |
| Q48029905 | NMDA Receptors in the Central Nervous System |
| Q26997407 | NMDA receptor modulators: an updated patent review (2013-2014) |
| Q41616016 | NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells |
| Q30432782 | NR2B Antagonist CP-101,606 Abolishes Pitch-Mediated Deviance Detection in Awake Rats |
| Q34094903 | Neuroprotective effect of penehyclidine hydrochloride on focal cerebral ischemia-reperfusion injury |
| Q48218430 | Optimization of Bicyclic Lactam Derivatives as NMDA Receptor Antagonists |
| Q44728149 | Potential involvement of GRIN2B encoding the NMDA receptor subunit NR2B in the spectrum of Alzheimer's disease. |
| Q37563518 | Prediction of N-Methyl-D-Aspartate Receptor GluN1-Ligand Binding Affinity by a Novel SVM-Pose/SVM-Score Combinatorial Ensemble Docking Scheme |
| Q38306583 | Retour aux sources: defining the structural basis of glutamate receptor activation |
| Q38195519 | Supraspinal metabotropic glutamate receptor subtype 8: a switch to turn off pain |
| Q48320720 | The Structure-Activity Relationship of a Tetrahydroisoquinoline Class of N-Methyl-d-Aspartate Receptor Modulators that Potentiates GluN2B-Containing N-Methyl-d-Aspartate Receptors. |
| Q38957856 | miR-137, a new target for post-stroke depression? |
Search more.